Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent.~* Postmenopausal females, 18 years of age or older.~* Histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of locally recurrent disease not amenable to resection or radiation therapy with curative intent, or metastatic disease.~* HER2 negative breast cancer. Central testing (required for all subjects) must demonstrate that the tumor is HER2 negative by FISH or Immunohistochemistry (IHC).~* ER positive breast cancer. Central testing (required for all subjects) must demonstrate that the tumor is ER+ with low expression (H-score \[1-159\]).~* Paraffin-embedded tumor block(s) or 15 to 20 unstained slides available for centralized assessment of ER, PR, and HER2.~* Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 or bone-only non measurable disease.~* Eastern Cooperative Oncology Group (ECOG) Performance status 0 or 1.~* Adequate hematological, hepatic and renal functions.~* Baseline left ventricular ejection fraction (LVEF) 50%.~* Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.~Exclusion Criteria:~* Brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease.~* Prior treatment with any type of systemic therapy for advanced disease.~* Prior treatment with letrozole in (neo)adjuvant setting with disease-free interval ≤ 12 months from completion of treatment until randomization.~* Prior treatment with any anti HER-family targeted therapy in (neo)adjuvant setting.~* Any concurrent or previous malignancy within 5 years prior to randomization, except for adequately and radically treated basal or squamous skin cancer, or carcinoma in situ of the cervix, or other non-invasive/in-situ neoplasm.~* Non-measurable disease according to RECIST 1.1, with the exception of bone-only non-measurable disease.~* Known pre-existing interstitial lung disease.~* Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom.~* History or presence of clinically relevant cardiovascular abnormalities as per investigator assessment.~* Any other concomitant serious illness or organ system dysfunction as per investigator assessment~* Any contraindication to oral agents.~* Active hepatitis B infection, active hepatitis C infection or known HIV carrier.~* Known or suspected active drug or alcohol abuse.~* Known hypersensitivity to afatinib or letrozole or the excipients of any of the trial drugs.~* Concomitant treatment with strong inhibitor of P-gp.~* Any ongoing acute clinically significant toxic effect of prior anticancer therapy or any persisting complication of prior surgery.~* Subjects with known history of keratitis, ulcerative keratitis or severe dry eye.~* Participation in the active phase of other clinical trials of investigational agents in which last study treatment was administered within 2 weeks prior to randomization

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Continuous regimen of oral Letrozole 2.5 mg daily
- Arm B (Type: EXPERIMENTAL): Continuous regimen of oral Letrozole 2.5 mg daily plus oral Afatinib 30 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility